Concert Pharmaceuticals, Inc. (CNCE) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Net Income Growth CNCE has had growing net income for the last 3 years
Price to Book (PBV) Ratio Overvalued price-to-book. CNCE stock price is overvalued by more than 1x the price-to-book value.
Debt-Equity Ratio (DER) CNCE equity is higher than it's debt.
Revenue CNCE has positive revenue for last 5 years

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth CNCE has never had growing revenue.
Net Income CNCE never has positive net income for 2 years.
Dividend Yield CNCE has low dividend yield (0%).
Return of Assets CNCE has low return of asset (-39.5%).
Return of Equity CNCE has low return of equity (-60.1%).
Return of Invested Capital CNCE has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-55,409,000 USD

Dividend

Financial Ratios

CEO

CEO Name

Dr. Roger Tung

Management

About Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Additional Information

Company name

Concert Pharmaceuticals, Inc.

Symbol

NASDAQ:CNCE

Exchange

NASDAQ Global Market

Industry

Biotechnology

Sector

Healthcare

Address

65 Hayden Ave Ste 3000N
Lexington
MASSACHUSETTS
US
02421

Website

https://www.concertpharma.com